Skip to main content
Full access
Letters to the Editor
Published Online: 1 October 2016

Ultra-Low-Dose Buprenorphine for Mental Pain: Response to Ruan et al.

To the Editor: Ruan et al. raise the possibility that ultra-low-dose buprenorphine reduces suicidal ideation, as it did in our double-blind, placebo-controlled trial (1), by alleviating physical pain. We agree with them that there is ample evidence to suggest that patients who suffer from physical pain are at high risk for suicidal ideation and suicidal acts (2). Adequate pain control may therefore decrease suicidality in such patients. However, most patients in our study did not suffer from physical pain.
All potential subjects in our trial underwent a workup that included a detailed medical history and a complete physical examination. Of the 88 patients in our intent-to-treat group, three were found to have fibromyalgia, and the rest were free of significant physical pain. Several other potential subjects were also found to have physical pain but were screened out because of medical illnesses or a history of heavy analgesic use.
Thus, while our findings do not prove that ultra-low-dose buprenorphine reduces suicidal ideation by decreasing mental pain, they do suggest that ultra-low-dose buprenorphine may serve as a quick-acting treatment for suicidal individuals, including those who are free of physical pain.
This raises the enduring question of the relationship between physical pain, mental pain, and suicidality. As reviewed by Elman et al. (2), several lines of evidence suggest that the colloquial terms “broken heart” and “heartache” may reflect a sad existential truth: mental pain hurts so much that it may lead to suicide.
Since Shakespeare’s “To be, or not to be” monologue, in which Prince Hamlet contemplates suicide in order to “end the Heart-ache” (3), mental pain has been associated with suicidality in poetry and prose. Many, and perhaps most, suicidal individuals who come to the attention of mental health professionals seek death not because they want to stop living but because they want to stop suffering.
In a recent systematic review, Verrocchio et al. concluded that “mental pain is a core clinical factor for understanding suicide” (4). Specifically, they found mental pain to be a stronger factor of vulnerability for suicidal ideation than depression.
Mood symptoms may be experienced and described as physical pain in some cultures, and mood and somatic symptoms are often positively correlated (5). However, we agree with Verrocchio et al. that mental pain “is no less real than other types of grief” (4).
In our opinion, clinicians should be open to the possibility—not the certainty—that judicious short-term use of ultra-low-dose buprenorphine may quickly decrease severe suicidal ideation by ameliorating the experience of mental pain.

References

1.
Yovell Y, Bar G, Mashiah M, et al: Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry 2016; 173:491–498
2.
Elman I, Borsook D, Volkow ND: Pain and suicidality: insights from reward and addiction neuroscience. Prog Neurobiol 2013; 109:1–27
3.
Thompson A, Taylor N (ed): Hamlet: The Texts of 1603 and 1623. Third Series (The Arden Shakespeare), vol. 2. London, Bloomsbury Arden, 2006
4.
Verrocchio MC, Carrozzino D, Marchetti D, et al: Mental pain and suicide: a systematic review of the literature. Front Psychiatry 2016; 7:108
5.
Arnault DS, Sakamoto S, Moriwaki A: Somatic and depressive symptoms in female Japanese and American students: a preliminary investigation. Transcult Psychiatry 2006; 43:275–286

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1043 - 1044
PubMed: 27690553

History

Accepted: July 2016
Published online: 1 October 2016
Published in print: October 01, 2016

Keywords

  1. Suicide
  2. Pain

Authors

Details

Yoram Yovell, M.D., Ph.D.
From the Institute for the Study of Affective Neuroscience, University of Haifa, Haifa, Israel.
Gali Bar, Ph.D.
From the Institute for the Study of Affective Neuroscience, University of Haifa, Haifa, Israel.

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share